Rationale, design, and baseline characteristicss of the effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection: EPIC-HIV randomized clinical trial
Author:
Matthew S. Durstenfeld,Marta Levkova-Clark,Danny Li,Veronica Schaffer,Shady Abohashem,Yifei Ma,Kosuke Kawai,Michael T. Lu,Irini Sereti,Steven G. Deeks,Ahmed Tawakol,Priscilla Y. Hsue
Publication:
American Heart Journal
© 2026 The Authors. Published by Elsevier Inc.